Dose-response curves reporting mean ± SD decrease in cell viability and corresponding average IC 50 values of cancer cell lines SK-MEL-147, WM88, and ONDA7, as well as normal cell lines LX-2, Hep-G2, and NHEM, treated with serially diluted defactinib for 96 h. Values reported for: SK-MEL-147 and LX-2 were derived from 4 biological replicates (n = 4); WM88 were derived from 3 biological replicates; ONDA7 were derived from 3 biological replicates; Hep-G2 were derived from 3 biological replicates; and NHEM were derived from 4 biological replicates.
